[HTML][HTML] State of the art in CAR T cell therapy for CD19+ B cell malignancies

MJ Frigault, MV Maus - The Journal of Clinical Investigation, 2020 - Am Soc Clin Investig
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations
of novel constructs being developed at a rapid pace. Since the initial reports of chimeric …

[HTML][HTML] Efficacy of tocilizumab in patients hospitalized with Covid-19

JH Stone, MJ Frigault, NJ Serling-Boyd… - … England Journal of …, 2020 - Mass Medical Soc
Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear. …

Differential expression and emerging functions of non-coding RNAs in cold adaptation

JJ Frigault, MD Morin, PJ Morin - Journal of Comparative Physiology B, 2017 - Springer
Several species undergo substantial physiological and biochemical changes to confront the
harsh conditions associated with winter. Small mammalian hibernators and cold-hardy …

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis

…, T Vuorinen, M Nordberg, M Valtonen, MJ Frigault… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …

[HTML][HTML] Dose–response correlation for CAR-T cells: a systematic review of clinical studies

A Rotte, MJ Frigault, A Ansari, B Gliner… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
The potential of chimeric antigen receptor (CAR) T cells to successfully treat hematological
cancers is widely recognized. Multiple CAR-T cell therapies are currently under clinical …

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

…, CL Phillips, A Keating, MJ Frigault… - Blood …, 2020 - ashpublications.org
Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for
treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic …

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two …

…, E Jones, K McGee, M Maus, M Frigault, J Brown… - The Lancet, 2020 - thelancet.com
Background Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor
(CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical …

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma

…, KME Gallagher, K Katsis, MJ Frigault, J Southard… - Nature medicine, 2022 - nature.com
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic
malignancies. Approximately half of patients with refractory large B cell lymphomas …

[HTML][HTML] Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity

…, DG Maloney, AK Gopal, MJ Frigault… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration
for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of durable …

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

…, SE McGettigan, MJ Frigault, J Lee… - Blood, The Journal …, 2014 - ashpublications.org
With the notable exception of B-cell malignancies, the efficacy of chimeric antigen receptor (CAR)
T cells has been limited, and CAR T cells have not been shown to expand and persist …